Nektar Therapeutics (NKTR) Bundle
A Brief History of Nektar Therapeutics
Company Overview
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. The company focuses on developing innovative medicines, particularly in the field of immunotherapy. Nektar's research has resulted in a pipeline targeting autoimmune diseases and cancer.
Recent Financial Performance
As of September 30, 2024, Nektar reported a total revenue of $69.25 million, representing a 5% increase from $66.24 million in the same period of the previous year. The breakdown of revenue sources is as follows:
| Revenue Source | 2024 (in millions) | 2023 (in millions) | Change (in millions) | Percentage Change |
|---|---|---|---|---|
| Product Sales | $20.69 | $15.20 | $5.49 | 36% |
| Non-cash Royalty Revenue | $48.03 | $50.86 | ($2.83) | (6%) |
| License, Collaboration, and Other Revenue | $0.53 | $0.18 | $0.36 | 198% |
Net Loss
Nektar reported a net loss of $126.22 million for the nine months ended September 30, 2024, which is a decrease of 46% compared to a net loss of $233.98 million for the same period in 2023. This improvement reflects a reduction in total operating costs and expenses, which decreased by 36% from $296.41 million in 2023 to $188.80 million in 2024.
Cash Flow and Liquidity
As of September 30, 2024, Nektar had approximately $249 million in cash and investments in marketable securities. The cash flow from operating activities for the nine months ended September 30, 2024, was $(129.52 million), compared to $(145.56 million) for the same period in 2023.
Key Business Developments
- On November 1, 2024, Nektar entered into an Asset Purchase Agreement to sell its manufacturing facility in Huntsville, Alabama, for $70 million in cash and a 20% equity stake in the purchaser.
- In February 2024, the company repurchased 8.3 million shares of its common stock from Bristol Myers Squibb for $3 million.
- Nektar entered into a long-term supply agreement with UCB that increased the selling price of PEG reagents, positively impacting future revenue.
Stockholder Equity
As of September 30, 2024, Nektar's total stockholders' equity was $48.88 million, a significant decrease from $130.99 million at the end of the previous year. The decrease is primarily attributed to the accumulated deficit, which stood at $(3.60 billion) as of September 30, 2024.
| Balance Sheet Item | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Total Assets | $307,966 | $398,033 | ($90,067) |
| Total Liabilities | $259,082 | $267,046 | ($7,964) |
| Total Stockholders' Equity | $48,884 | $130,987 | ($82,103) |
A Who Owns Nektar Therapeutics (NKTR)
Current Ownership Structure
As of September 30, 2024, Nektar Therapeutics has a total of 192,743,000 shares issued, with 184,458,000 shares outstanding. The company's stock is traded on the NASDAQ exchange under the ticker symbol NKTR.
Major Shareholders
The following table outlines the major shareholders of Nektar Therapeutics as of 2024:
| Shareholder | Shares Held | Percentage Ownership |
|---|---|---|
| Bristol-Myers Squibb Company | 8,285,000 | 4.28% |
| TCG Crossover Fund II, L.P. | 25,000,000 (upon exercise of pre-funded warrants) | 12.92% |
| Healthcare Royalty Management, LLC | — | — |
| Institutional Investors (various) | ~60,000,000 | ~31.1% |
| Insider Holdings (Executives and Directors) | ~5,000,000 | ~2.59% |
Institutional Ownership
As of the latest filings, institutional investors own approximately 31.1% of Nektar Therapeutics. The largest institutional shareholders include:
| Institution | Shares Held | Percentage Ownership |
|---|---|---|
| Vanguard Group, Inc. | ~10,000,000 | ~5.19% |
| BlackRock, Inc. | ~9,000,000 | ~4.67% |
| State Street Corporation | ~8,000,000 | ~4.16% |
| Other Institutional Investors | ~33,000,000 | ~17.08% |
Recent Transactions
In 2024, Nektar Therapeutics repurchased 8.3 million shares from Bristol-Myers Squibb for $3.0 million. Additionally, the company issued a pre-funded warrant to TCG Crossover Fund II for 25 million shares, generating gross proceeds of $30 million.
Financial Overview
Nektar Therapeutics reported a net loss of $126.222 million for the nine months ended September 30, 2024. The company's total stockholders' equity as of September 30, 2024, was $48.884 million.
Cash Position
As of September 30, 2024, Nektar Therapeutics had approximately $249 million in cash and investments in marketable securities.
Future Outlook
Nektar expects to continue incurring substantial losses while focusing on advancing its clinical-stage drug candidates.
Nektar Therapeutics (NKTR) Mission Statement
Company Overview
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. The company is headquartered in San Francisco, California, and is incorporated in Delaware. Nektar aims to create new immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes.
Mission Statement
The mission of Nektar Therapeutics is to revolutionize the treatment of cancer and autoimmune diseases through the development of novel immunotherapies. The company is dedicated to advancing its pipeline of clinical-stage and preclinical-stage immunomodulatory agents, including rezpegaldesleukin and NKTR-255.
Financial Overview
As of September 30, 2024, Nektar Therapeutics reported a net loss of $126.2 million for the nine-month period ending on that date, compared to a net loss of $234.0 million for the same period in the previous year. The company had approximately $249.0 million in cash and investments in marketable securities.
| Financial Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Loss | $37.1 million | $45.8 million | (19%) |
| Total Revenue | $24.1 million | $24.1 million | (0%) |
| Cash and Cash Equivalents | $30.1 million | $64.9 million | (54%) |
| Research and Development Expenses | $35.0 million | $24.1 million | 46% |
| General and Administrative Expenses | $19.0 million | $21.1 million | (10%) |
Collaboration Agreements
Nektar Therapeutics has historically derived its revenue from collaboration agreements and partnerships. The company receives upfront fees, research and development reimbursements, milestone payments based on clinical or regulatory achievements, royalties, and product sales. The collaboration with Eli Lilly for rezpegaldesleukin is a key component of Nektar's strategy, particularly as they explore new indications for this drug.
Recent Developments
In March 2024, Nektar entered a Securities Purchase Agreement with TCG Crossover Fund II, L.P., issuing a pre-funded warrant to purchase 25 million shares of common stock at a price of $1.20 per share, generating gross proceeds of $30 million. Additionally, the company has been engaged in significant restructuring efforts, including a 70% workforce reduction in 2022 and a 60% reduction in 2023, aimed at optimizing its operational efficiency.
Pipeline Overview
Nektar's pipeline includes several promising candidates in various stages of development. Rezpegaldesleukin is currently undergoing clinical trials for multiple autoimmune conditions, with ongoing studies aimed at moderate-to-severe atopic dermatitis and severe alopecia areata. The company is committed to advancing its research and clinical trials to bring innovative therapies to market.
Conclusion
The mission of Nektar Therapeutics encapsulates its commitment to advancing immunotherapy development, focusing on innovative solutions for cancer and autoimmune diseases. Despite ongoing financial losses, the company is strategically positioned to leverage its collaborations and research capabilities to achieve long-term success.
How Nektar Therapeutics (NKTR) Works
Company Overview
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines, particularly in the field of immunotherapy. As of September 30, 2024, the company had approximately $249.0 million in cash and investments in marketable securities.
Revenue Streams
Nektar's revenue primarily comes from collaboration agreements, which can include:
- Product sales
- Royalties
- License fees
- Development and sales milestones
Financial Performance
For the nine months ended September 30, 2024, Nektar reported the following financial results:
| Financial Metric | 2024 | 2023 | % Change |
|---|---|---|---|
| Total Revenue | $69,252,000 | $66,237,000 | 5% |
| Product Sales | $20,689,000 | $15,198,000 | 36% |
| Net Loss | $(126,222,000) | $(233,977,000) | 46% |
| Basic and Diluted Net Loss per Share | $(0.62) | $(1.23) | 50% |
Operating Costs and Expenses
In the same period, Nektar's operating costs and expenses included:
| Expense Type | 2024 | 2023 |
|---|---|---|
| Cost of Goods Sold | $22,709,000 | $26,485,000 |
| Research and Development | $92,163,000 | $84,220,000 |
| General and Administrative | $59,616,000 | $60,097,000 |
| Total Operating Costs and Expenses | $188,798,000 | $296,410,000 |
Clinical Pipeline
Nektar is focused on developing several drug candidates, notably:
- Rezpegaldesleukin: targeting autoimmune diseases.
- NKTR-255: aimed at cancer treatment.
Recent Developments
On November 1, 2024, Nektar entered into an agreement to sell its manufacturing facility in Huntsville, Alabama, for $70 million in cash, alongside receiving a 20% equity stake in the purchasing entity.
Liquidity and Capital Resources
The company's cash flow activities for the nine months ended September 30, 2024, included:
| Cash Flow Activity | Amount |
|---|---|
| Net Cash Used in Operating Activities | $(129,522,000) |
| Net Cash Provided by Investing Activities | $82,356,000 |
| Net Cash Provided by Financing Activities | $42,035,000 |
Stockholder Equity
As of September 30, 2024, Nektar's stockholder equity was reported as follows:
| Equity Metric | Amount |
|---|---|
| Total Stockholders' Equity | $48,884,000 |
| Accumulated Deficit | $(3,603,471,000) |
How Nektar Therapeutics (NKTR) Makes Money
Revenue Sources
Nektar Therapeutics generates revenue primarily through collaboration agreements, which can yield various income streams, including:
- Product sales
- Royalties and license fees
- Milestone payments
- Development and sales milestones
For the nine months ended September 30, 2024, Nektar reported total revenue of $69.252 million, compared to $66.237 million for the same period in 2023, marking a 5% increase.
| Revenue Source | 2024 (9 months) | 2023 (9 months) | Change ($) | Change (%) |
|---|---|---|---|---|
| Product Sales | $20.689 million | $15.198 million | $5.491 million | 36% |
| Non-cash Royalty Revenue | $48.029 million | $50.860 million | ($2.831 million) | (6%) |
| License, Collaboration, and Other Revenue | $534,000 | $179,000 | $355,000 | 198% |
| Total Revenue | $69.252 million | $66.237 million | $3.015 million | 5% |
Product Sales
Product sales are largely influenced by fixed-price manufacturing and supply agreements with collaboration partners. For the three months ended September 30, 2024, product sales were $8.015 million, compared to $5.822 million for the same period in 2023, reflecting an increase of 38%.
Collaboration Agreements
Nektar has entered into several collaboration agreements, which have historically provided substantial revenue. The company’s agreements often include:
- Upfront fees
- Milestone payments based on clinical and regulatory achievements
- Royalties from sales of commercialized products
For instance, Nektar has a collaboration agreement with UCB related to dapirolizumab pegol, entitling it to up to $40 million in regulatory approval milestones, along with royalties based on net sales.
Financial Performance
For the nine months ended September 30, 2024, Nektar's operating costs totaled $188.798 million, compared to $296.410 million in the same period of 2023, reflecting a decrease of 36%. This reduction is largely attributed to a significant impairment charge of $76.501 million recorded in 2023.
| Operating Costs | 2024 (9 months) | 2023 (9 months) | Change ($) | Change (%) |
|---|---|---|---|---|
| Cost of Goods Sold | $22.709 million | $26.485 million | ($3.776 million) | (14%) |
| Research and Development | $92.163 million | $84.220 million | $7.943 million | 9% |
| General and Administrative | $59.616 million | $60.097 million | ($481,000) | (1%) |
| Total Operating Costs | $188.798 million | $296.410 million | ($107.612 million) | (36%) |
Net Loss
Nektar reported a net loss of $126.222 million for the nine months ended September 30, 2024, compared to a net loss of $233.977 million for the same period in 2023, representing a decrease of 46%.
Liquidity and Capital Resources
As of September 30, 2024, Nektar had approximately $249 million in cash and investments in marketable securities. The company has financed its operations through revenue from collaboration agreements, royalties, and public and private placements of debt and equity securities.
Recent Transactions
In 2024, Nektar entered into several significant transactions, including:
- A sale agreement for its manufacturing facility in Huntsville, AL, for approximately $70 million.
- A securities purchase agreement with TCG Crossover Fund II, L.P., generating $30 million in gross proceeds.
- An amendment to the 2020 Purchase and Sale Agreement with HCR, resulting in a $15 million payment to Nektar.
Nektar Therapeutics (NKTR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Nektar Therapeutics (NKTR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Nektar Therapeutics (NKTR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Nektar Therapeutics (NKTR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.